A lack of targeting accuracy and radiosensitivity severely limit clinical radiotherapy. In this study, we developed Ru-based metal-organic nanostructures (MONs) radiosensitizer (ZrRuMn-MONs@mem) to optimize irradiation by maximizing reactive oxygen species (ROS) generation and CO release in X-ray-induced dynamic therapy (XDT). The well-designed nanostructures increase the direct absorption of radiation doses (primary radiation) and promote the deposition of photons and electrons (secondary…
Angew Chem Int Ed Engl. 2022 Oct 2. doi: 10.1002/anie.202211674. Online ahead of print.
ABSTRACT
A lack of targeting accuracy and radiosensitivity severely limit clinical radiotherapy. In this study, we developed Ru-based metal-organic nanostructures (MONs) radiosensitizer (ZrRuMn-MONs@mem) to optimize irradiation by maximizing reactive oxygen species (ROS) generation and CO release in X-ray-induced dynamic therapy (XDT). The well-designed nanostructures increase the direct absorption of radiation doses (primary radiation) and promote the deposition of photons and electrons (secondary radiation). Intriguingly, the secondary electrons were trapped and transferred in this constrained MONs and induce a cascade of reactions to increase the therapeutic efficiency. Meanwhile, the full-length antiglypican 3 (GPC3) antibody (hGC33) expressed cell membrane coating enabled actively tumor sites targeting with optimized biocompatibility. These results indicate that the ZrRuMn-MONs@mem represent a starting point for advancing an all-around radiosensitizer to potentiate clinical XDT efficiency.
PMID:36184566 | DOI:10.1002/anie.202211674